What records are connected here?
- Evidence lanes
- 3
- Source years
- 19
- Drugs@FDA applications
- 14
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsHeart and blood vessels
Also called Angiomax2
Bivalirudin is a synthetic peptide of 20 amino acids that directly blocks thrombin, the enzyme that forms blood clots. It was first approved in the United States as Angiomax.1,2 Its U.S. label covers use as an anticoagulant during percutaneous coronary intervention (PCI), the procedure that opens narrowed heart arteries, including in people with heparin-induced thrombocytopenia.1 In the Bivalirudin Angioplasty Trial of 4,312 people, it was not shown to be better than heparin at preventing death, heart attack or vessel closure; event rates were similar. The label warns that it increases bleeding risk.1
| What it is | A synthetic 20-amino-acid peptide that binds both the active site and a second binding site of thrombin, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Angiomax with an original approval date of December 15, 2000. The cited label has no boxed warning.1,2 |
| Human evidence | Randomized trials comparing it with heparin in people undergoing coronary procedures, and a single-arm study in 51 people with heparin-induced thrombocytopenia, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Bivalirudin is a synthetic peptide of 20 amino acids and a specific, reversible direct thrombin inhibitor, according to the label.1
Drugs@FDA lists the original application, Angiomax (NDA 020873), now held by Sandoz. Several other companies also hold approvals for bivalirudin.2
The label states that bivalirudin binds both the catalytic site and the anion-binding exosite of thrombin, whether thrombin is circulating or bound in a clot.1
Thrombin turns fibrinogen into fibrin, the mesh of a clot, and activates other clotting factors, so blocking it slows clot formation, according to the label.1
In the Bivalirudin Angioplasty Trial, 4,312 people with unstable angina undergoing angioplasty were randomized to bivalirudin or heparin. The label states the studies did not show bivalirudin to be superior for death, heart attack, vessel closure or worsening needing further procedures, and that these events occurred at similar rates.1
In the same trials, 3.7% of people given bivalirudin had major bleeding events, according to the label.1
The label also describes a single-arm study of 51 people with heparin-induced thrombocytopenia who underwent PCI with bivalirudin.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Angiomax, application NDA 020873, with an original approval date of December 15, 2000.2
The bivalirudin label cited here (DailyMed SPL version 5, published July 29, 2026) states that it is indicated as an anticoagulant in patients undergoing PCI, including patients with heparin-induced thrombocytopenia or heparin-induced thrombocytopenia and thrombosis syndrome.1
The label has no boxed warning. It is contraindicated in active major bleeding, and its warnings state that bivalirudin increases the risk of bleeding.1
The label states that the clinical relevance of its laboratory clotting-test effects is unknown.1
How it compares with current alternatives beyond heparin, since the trials described in the label compared it mainly with heparin.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Bivalirudin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Bivalirudin are a bounded selection, not every registration or paper about Bivalirudin. For the years before Bivalirudin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Bivalirudin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Bivalirudin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Angiomax and generics as an anticoagulant during coronary procedures. Randomized trials of 4,312 people described in the label found event rates similar to heparin. The label warns that bivalirudin increases the risk of bleeding.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Angiomax and generics as an anticoagulant during coronary procedures. Randomized trials of 4,312 people described in the label found event rates similar to heparin. The label warns that bivalirudin increases the risk of bleeding.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date November 9, 2026
Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.↗Added to PeptideScanner November 15, 2026Literature metadata · added November 15, 2026
Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review.↗Source date November 9, 2026Literature metadata · added November 15, 2026
Bivalirudin versus heparin in adult and pediatric patients with extracorporeal membrane oxygenation therapy: A systematic review and meta-analysis.↗Source date November 9, 2026Literature metadata · added November 15, 2026
Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis.↗Source date November 9, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
28 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.
A phase value is unavailable here for 2 selected records; this is not counted as “no phase.”
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00043940 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-09-16, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00073580 at 2026-11-15T21:58:19.888Z. Its registry update date was 2018-11-30, and PeptideScanner's reviewed identity mapping was bivalirudin.
PeptideScanner retained ClinicalTrials.gov record NCT00073593 at 2026-11-15T21:58:19.888Z. Its registry update date was 2011-11-10, and PeptideScanner's reviewed identity mapping was bivalirudin.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span September 23, 1998 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 29461391 in Anesthesia and analgesia as Journal Article, Review, with publication-date metadata of 2019-01 (month precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35065202 in Pharmacological research as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2022-01-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35098565 in British journal of clinical pharmacology as Journal Article, Meta-Analysis, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-02-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 35616224 in Perfusion as Journal Article, Meta-Analysis, with publication-date metadata of 2022-05-26 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 36355803 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Meta-Analysis, Systematic Review, Journal Article, with publication-date metadata of 2022-11-09 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 36449392 in Journal of pharmacy practice as Meta-Analysis, Journal Article, with publication-date metadata of 2022-11-30 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 37865864 in Coronary artery disease as Meta-Analysis, Journal Article, with publication-date metadata of 2023-09-20 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39259286 in Journal of cardiovascular pharmacology as Journal Article, Review, with publication-date metadata of 2024-12-01 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 39585174 in Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies as Journal Article, Randomized Controlled Trial, Comparative Study, with publication-date metadata of 2024-11-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 42862663 in Annals of cardiac anaesthesia as Journal Article, Systematic Review, Meta-Analysis, Comparative Study, with publication-date metadata of 2026-10-12 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03537586 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was bivalirudin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04278404 at 2026-11-15T21:58:19.888Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was bivalirudin.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026